Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Early Failure Is Like Yeast: Early Triage Boosts Big Pharma's R&D Productivity - Tufts

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

One of the strengths of the big pharma R&D model is the ability to triage candidates early in development, a recent study of R&D productivity at the top 50 pharmaceutical firms by the Tufts Center for the Study of Drug Development suggests.

You may also be interested in...



Has FDA Reached A "New Normal"? Parexel Thinks Lower Review Metrics May Be Here To Stay, Though FDA Hopes To Improve

Shortly after the third anniversary of the FDA Amendments Act, the repercussions of FDA's new authorities and responsibilities for drug review performance are becoming clearer

Parexel Sees Surge In NME Filings, But Also Lower Chance Of Approval

Parexel welcomed signs of a recovery in the submissions of new molecular entities for FDA approval during 2009, floating the possibility that one major reason for the relative drought in truly new drugs entering the market in the last several years - declines in industry R&D productivity - may be easing up

First Cycle Approval Rate Tops 50% For 2006 NMEs; Merck Hits 100%

Merck skillfully navigated FDA’s approval process in 2006, receiving all five of its new molecular entity and novel biologic approvals after only a single review cycle.

Related Content

Topics

UsernamePublicRestriction

Register

PS004549

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel